LABT — Lakewood-Amedex Biotherapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2079272 ·
Last close
$2.02
Market Cap
$3.54M
52W High
$46.10
52W Low
$1.66
ADV30
3,007,569
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -886,750 | -923,291 | 196,343 | 11,709 | 3,037,991 |
| Dec 2025 | 0 | — | -712,060 | -744,918 | 481,598 | 236,400 | 2,446,135 |
| Sep 2025 | 0 | — | -1,880,317 | -1,907,159 | 985,118 | 658,410 | 2,251,434 |
| Mar 2025 | 0 | — | -542,609 | -539,617 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,914,001
Investing CF
$841,000
Financing CF
$325,000
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.76
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-54,274,421
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-3,999,835
Pretax Income TTM
$-4,114,985
Interest Exp TTM
$115,150
Analysts
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -3,772,370 | -3,847,637 | 481,598 | 2,446,135 | — | -1,944,698 |
| Dec 2024 | 0 | -4,026,820 | -4,855,405 | 1,070,581 | 660,970 | — | -5,723,322 |
| Dec 2023 | 0 | -8,636,719 | -8,281,960 | 6,893,904 | 2,335,577 | — | -6,816,114 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GOVX | GeoVax Labs, Inc. | $3.55M | $0.68 | — |
| FBLG | FibroBiologics, Inc. | $3.65M | $0.70 | — |
| XRTX | XORTX Therapeutics Inc. | $3.67M | $2.12 | — |
| REVB | REVELATION BIOSCIENCES, INC. | $3.71M | $0.95 | — |
| ERNA | Ernexa Therapeutics Inc. | $3.83M | $3.28 | — |
News headlines (Yahoo Finance, 1h cache)
Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
2026-07-22 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
2026-07-15 12:02 · Yahoo
CEO Chat with Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics
2026-07-13 16:35 · Yahoo
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
2026-07-07 12:02 · Yahoo
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
2026-06-26 12:35 · Yahoo
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers
2026-06-25 12:02 · Yahoo
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
2026-06-23 12:35 · Yahoo
LABT: Initiating Coverage of Lakewood-Amedex; Building a Next-Generation Antimicrobial Platform
2026-06-23 09:20 · Yahoo
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections
2026-06-22 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
2026-06-16 12:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.